Abstract: Objective The aim of this study was to explore the prediction of response to peginterferon alfa-2a by blood interferon lambda 4（IFNL4） and interleukin-28B（IL-28B） gene polymorphisms in patients with chronic hepatitis B（CHB）. Methods 140 patients with CHB were enrolled in our hospital between March 2015 and March 2017,and all the patients were given peginterferon alfa-2a for antiviral therapy for 12 months. The blood genetic polymorphisms of IFNL4 and IL-28B were assayed by PCR. Results At the end of discontinuation of the regimen,108 patients （77.1%） responded,and 32 （22.9%） didn’ t responded to the anti-viral therapy;the percentage of IL-28Brsrs8099917 type TT was 88.9%,significantly higher than 68.8% （P<0.05） in non-responders;serum ALT,AST and HBV DNA levels in responders were（35.4±3.2） U/L,（38.6±2.1） U/L and （3.8±2.1） lg copies/ml,significantly lower than （61.5±4.8） U/L,（73.5±3.0） U/L and （5.2±3.1） lg copies/ml （P<0.05） in non-responders;serum ALT,AST and HBV DNA levels in 125 patients with IFNL4 type TT/TT were（47.1±2.5）U/L, （49.1±1.6） U/L and （4.5±1.2） lg copies/ml,not significantly different as compared to （48.0±2.1） U/L,（59.4±1.5）U/L and （4.7±1.3） lg copies/ml in 15 patients with type TT/△G （P>0.05）;serum ALT,AST and HBV DNA levels in 118 patients with IL-28B type TT were（36.4±2.1） U/L,（38.9±2.7） U/L and（4.0±1.7） lg copies/ml,significantly lower than [（59.0±1.4） U/L,（72.1±1.1） U/L and （6.0±2.1） lg copies/ml,respectively,P<0.05] in 22 patients with type TG. Conclusion The majority of CHB patients have genotype TT/TT of IFNL4rs368234815 and genotype TT of IL-28Brs8099917,and the detection of IL-28B gene polymorphism might,and that of IFNL4 polymorphism might not predict the response to anti-viral therapy in patients with CHB,which needs further investigation.

Key words: Chronic hepatitis B, Peginterferon alfa-2a, Interferon lambda 4, Interleukin-28B, Response, Prediction